Lexicon studies show positive financial impact of Inpefa to be presented at AMCP

Lexicon Pharmaceuticals highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA( sotagliflozin, at the Academy of Managed Care Pharmacy AMCP Nexus 2023 National Meeting, October 16-19 at the Orlando World Center Marriott, Expo Hall, Cypress 1 and 2, Orlando, Florida. “Economic impact of sotagliflozin among patients with heart failure: Budget impact analysis from US payer perspective”The objective of this study was to quantify the payer budget impact of sotagliflozin following FDA approval in May 2023, and market entry one month later. The budget impact was modeled as the change in medical and pharmacy costs from using sotagliflozin in addition to the standard of care SoC compared with the SoC alone among U.S. patients hospitalized with heart failure HF . Costs included pharmacy, inpatient, emergency department visits, and other medical and adverse event costs. Budget impact was measured separately for commercial payer and all-payer scenarios…The authors concluded that “Health plans adopting sotagliflozin can expect to see an increase in pharmacy costs, but about one-third of this cost was offset by lower medical